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ABSTRACT
Some 30% of contemporary cardiology patients
have coexisting known diabetes, and another
40% have either undiagnosed diabetes or
prediabetes. There is still no final conclusive
evidence of cardiovascular benefit by good
glycemic control in type 2 diabetes, although
studies like the United Kingdom Prospective
Diabetes Study (UKPDS) and the Prospective
Pioglitazone Clinical Trial in Macrovascular
Events, and meta-analyses based on these and
other randomized controlled trials of blood
glucose-lowering therapies have been
encouraging. On the other hand,
microvascular disease is clearly reduced by
good glycemic control. Structured education
has remained a mandatory prerequisite of any
successful treatment. Not only is appropriate
weight management by diet and exercise able to
revert new onset diabetes to normal, but it is
also the foundation of any successful
pharmacotherapy of diabetes. Aiming at
normal fasting plasma glucose concentrations
of 5.3 mmol/L or 95 mg/dL appears to be safe
since publication of the long-term outcome
results of the Outcome Reduction with
an Initial Glargine INtervention trial.
Individualized target glycosylated hemoglobin
levels as near to normal as safely possible (i.e.,
\7% and avoiding hypoglycaemia) are the goal
for glycemic control. Hypoglycemia seems to
emerge as a real concern in cardiology patients.
Based on the findings of UKPDS, including the
‘‘legacy’’ study, metformin is the most widely
recommended first-line drug therapy in type 2
diabetes, also in terms of preventing
cardiovascular complications. An alternate
first-line option in some parts of the world,
especially Asian countries, is the class of alpha-
glucosidase inhibitors. In most patients,
combination therapies with two or three
classes of drugs are warranted. Early
combination are the golden strategy as type 2
diabetes is a multi-causal disease; the various
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classes of drugs have distinct and synergistic
modes of action, and the blood glucose-
lowering efficacy of these drugs is more or less
fully maintained in combination. The recent
joint American Diabetes Association/European
Association for the Study of Diabetes position
statement mentions five options as step two of
the treatment algorithm for combination
with metformin: sulfonylureas, pioglitazone,
dipeptidyl peptidase-4 inhibitors, glucagon-like
peptide-1 agonists, and basal insulin.
Keywords: Alpha-glucosidase inhibitors; Diet;
Dipeptidyl peptidase-4 inhibitors; Exercise;
Lifestyle; Sulfonylureas; Thiazolidinediones;
Type 2 diabetes mellitus
INTRODUCTION
The worldwide epidemic of diabetes mellitus
has also reached the field of cardiology, with
some 30% of contemporary cardiology patients
having coexisting known diabetes [1]. In
addition, as many as 10–15% of cardiology
patients have previously undiagnosed diabetes
and another quarter have impaired glucose
tolerance (IGT) or prediabetes, as the Euro
Heart Survey and other epidemiologic
evaluations have shown [1–3]. In fact, diabetes
mellitus has remained to be an independent
cardiovascular (CV) risk predictor, which
doubles the risk of CV morbidity and
mortality, despite the progress made in
interventional and conservative cardiology in
recent years [4–6].
Glycemic control is a common challenge in
cardiology patients, especially in light of the
observational results obtained in the Euro Heart
Survey, that early and immediate appropriate
glycemic therapy appears to be of benefit in CV
patients [7]. It should be emphasized, however,
that although improved glycemic control seems
to be very important to reduce the
microvascular complications of diabetes in the
kidneys and the eyes, the current evidence is
not particularly strong in that it also reduces
macrovascular complications, such as CV
events [4, 8]. On the other hand, fears that
overambitious therapy trying to reach glycemic
goals in or close to the normal range may be
hazardous in its own right and increased
mortality has not been confirmed by the
6-year outcome results of the randomized,
controlled Outcome Reduction with an Initial
Glargine INtervention (ORIGIN) trial released in
June 2012 [9]. Nevertheless, hypoglycemia as a
complication of blood glucose-lowering therapy
has emerged to be associated with increased CV
mortality, not necessarily as a causative factor,
but rather as a surrogate of increased CV risk.
In aggregate, glycemic control is a common
problem in cardiology patients that not only
affords a lot of medical expertise, but also
complex resources, since it can only be dealt
with by intensive lifestyle management,
medical education, and training. The present
paper attempts, based on current guidelines [8,
10–12], to give some guidance for cardiologists
to integrate care for coexisting diabetes in their
patients and, hence, to summarize key aspects
in achieving appropriate glycemic control in
these patients.
METHODS
Up to November 2012, all published CV
outcome studies evaluating available blood
glucose-lowering therapies in patients with
type 2 diabetes in randomized controlled trials,
apart from studies in critically ill patients, were
included in this review and discussed in the
context of current guidelines [8, 10–12].
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STRUCTURED EDUCATION
Diabetes may affect all aspects of daily life.
Structured education, therefore, is a mandatory
prerequisite of any successful treatment [8, 10–
12] (Fig. 1). This is best achieved by a diabetes
team where the physician is the director of all
diagnostic and therapeutic measures, but
trained and certified diabetes nurses and
educators are in charge of the structured
education approach. Subjects to be covered are
pathogenesis of diabetes; blood glucose
monitoring; nutrition; physical activity and
healthy lifestyle; diabetes drugs, including the
appropriate administration; hypoglycemia and
its prevention; early diagnosis of microvascular,
neuropathic, and macrovascular complications
of diabetes and their prevention; and a wide
spectrum of psychosocial issues and quality of
life. Skills to be trained include blood glucose
monitoring; managing the daily meal plan;
insulin application if warranted; foot care; and
body hygiene.
Adequate information, education, and
training of patients with diabetes are
principally a lifelong task. For a start, an
interactive group approach based on diabetes
classes, which is quality certified on a regular
basis and lead by the already mentioned
diabetes educators or nurses, has turned out to
be the most effective and resource-saving
strategy. The earlier the structured education is
started, the better the lifelong success for the
patient. If the care-providing institution is not
equipped with the necessary resources to
perform the complex education process on its
own (e.g., upon the diagnosis of new diabetes),
the opportunity for education and training
should be provided in cooperation with
specialized diabetes care centres. More
individualized refresher courses may be
warranted in case of hypoglycemia or if
dietary failure becomes a problem. Evaluation
of home glucose measurements, however, in
conjunction with the attained concurrent
glycosylated hemoglobin (HbA1c) value, the
Fig. 1 Management of patients with type 2 diabetes: cardiovascular (CV) considerations. CHD coronary heart disease,
CHF congestive heart failure
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search for intermittent hypoglycemia, and
questions regarding the daily lifestyle pattern
are within the responsibility of every physician
providing care for patients with diabetes at
every visit to the clinic.
HEALTHY LIFESTYLE: A POWERFUL
TREATMENT TOOL
Not only is appropriate weight management by
diet and exercise highly effective to prevent the
development of type 2 diabetes at the level of
IGT, but it is also the foundation of every
successful therapy for diabetes [13–15] (Fig. 1).
One of the striking successes in the United
Kingdom Prospective Diabetes Study (UKPDS)
was the achievement of an initial mean weight
loss of approximately 4 kg for the whole group,
which transformed into a decrease of HbA1c
from approximately 9% to 7% after 3 months
[16]. A stringent 600 kcal/day diet is able to
‘‘cure’’ new onset type 2 diabetes [17]. A nearly
immediate normalization of fasting plasma
glucose (FPG) in most cases is followed by a
decrease of both hepatic and pancreatic fat
content, along with a restoration of insulin
secretion and a normalization of HbA1c [17].
Results like this underline the importance of
ectopic fat disposition, e.g., in the liver and the
pancreas (but also in the heart and muscle), as a
precipitating factor for the manifestation of type
2 diabetes, which certainly has a strong and
complex genetic background. An easy surrogate
measure of ectopic fat is waist circumference. As
a goal, waist circumference should be \94 cm
(37 in.) in men (\90 cm = 35.4 in. in Asian men)
and\80 cm (31.5 in.) in women [18].
The long-term randomized controlled
Action for Health in Diabetes (LOOK AHEAD)
study in type 2 diabetic patients has proven
the principal benefits of intensive lifestyle
management, including regular physical
activity, on metabolic control at its 1-year and
4-year follow-up [19, 20], but presented some
mixed results in terms of CV outcomes at the
end of the study [21]; an average initial weight
loss of 8.6% was followed by a significant
decrease in HbA1c and a reduced use of blood
glucose-lowering drugs as compared to the
‘‘regular educational support and care’’ group.
At the same time, a significant positive effect on
blood pressure and lipid control, though not
specifically on low-density lipoprotein (LDL)-
cholesterol, was seen in the intensive group,
necessitating a more intense poly-
pharmacotherapy in the standard group.
Although a slight rebound phenomenon was
observed after 4 years, the principle advantages
of intensive lifestyle management in terms of
weight loss and physical fitness were
maintained; thus, demonstrating the potential
of long-term efficacy on metabolic control.
Despite a continued weight reduction of 5%
over an 11-year follow-up, the LOOK AHEAD
study was halted due to futility to reduce pre-
specified CV outcomes, i.e., lower body weight
and increased physical fitness in the intensive
lifestyle management group did not materialize
into a reduced rate of long-term CV
complications in the context of this study,
perhaps against the background of a much
more intense drug therapy of CV risk factors
in the ‘‘standard’’ group [21]. On the other
hand, no harm was observed with intensive
lifestyle management and the detailed results at
termination are yet to be published.
The contribution of regular physical activity
to successful lifestyle management and good
metabolic control is often underestimated. Even
modest activities seem to be helpful. Regular
walking, i.e., more than 4 h a week (although
preferably 5.5 h) is markedly effective to reduce
HbA1c, blood pressure, and blood lipids, and
body weight in the long term [22].
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123
For the time being, appropriate lifestyle
management in type 2 diabetic patients has a
strong evidence class I, level A recommendation
in most guidelines [8, 10–12, 23].
TREATMENT TARGETS
The debate over the appropriate glycemic
targets and whether aiming at too low HbA1c
levels (i.e., \6.5% or even 6.0%) may be
hazardous has markedly settled down since
the publication of the ORIGIN trial [9]. In this
randomized, controlled, and prospective study
in a total of 12,537 type 2 diabetic patients with
high CV risk, including 760 patients with new
screen-detected diabetes and 1,452 subjects
with IGT/impaired fasting glucose, fasting
normoglycemia (\5.3 mM or 95 mg/dL FPG)
was targeted with long-acting insulin glargine
in the intensive arm and compared to a more
conservative approach using metformin and/or
sulfonylureas as deemed necessary in the
control arm. Mean FPG levels below this
threshold were attained long term (median
follow-up 6.2 years) in the glargine group
together with very slowly rising HbA1c levels
from 5.9% at 1 year to 6.2% at 7 years. HbA1c
concentrations ranged within or very close to
the normal range with glargine insulin therapy,
whereas in the control group mean HbA1c was
6.5% and mean FPG was 6.8 mmol/L or 123 mg/
dL [9]. Importantly, no negative outcomes of
this intensive normalization approach were
detectable, neither in terms of a composite
primary outcome consisting of CV death and
nonfatal myocardial infarction or stroke, nor in
terms of the single components thereof.
Furthermore, no negative outcomes were
detected in terms of an extended secondary
CV outcome, including hospitalizations for
heart failure or revascularizations, nor in terms
of overall mortality, and cancer development
and death [9]. In addition, the large subgroup of
60% of the population in ORIGIN with
preexisting CV events showed similar results
to the total population. This suggests that
targeting normoglycemia is safe, provided the
rate of severe hypoglycemic episodes is as low as
in ORIGIN, i.e., at about 1.0 per 100 patient
years [9]. On the other hand, no discernable
reduction of hard CV outcomes was seen over
the observation period of 6.2 years, along with
the rather small difference of HbA1c of 0.3%
between the two treatment groups [9].
Earlier than the ORIGIN trial, the active arm of
the Action to Control Cardiovascular Risk in
Diabetes study (ACCORD; 10,251 type 2 diabetic
patients with mean diabetes duration of
approximately 10 years at baseline), aiming at a
HbA1c level B6%, was stopped prematurely
because of a 30% increased risk of total and CV
mortality. The reasons for this observation,
however, have remained not fully elucidated,
although a fourfold higher rate of severe
hypoglycemia compared to the ORIGIN trial;
was apparent together with a marked average
weight gain of [3 kg [24]. Furthermore, raising
HbA1c deliberately to a mean of 7.2% did not
abolish the excessive mortality over the next
18 months, which excludes too low levels of
HbA1c as a cause of mortality. Also, the excessive
mortality was exhibited in those failing to reach a
primary HbA1c target of B6.0% in the ACCORD
study and struggling with a rather aggressive
escalation of blood glucose-lowering therapy at
HbA1c levels of 8 and 9%, whereas those achieving
a goal of approximately 6.0% HbA1c actually
benefited from the glycemic normalization
approach. Most patients failing glycemic targets
in the intensive arm of the ACCORD study were
on a fivefold blood glucose-lowering therapy with
a long-acting sulfonylurea, rosiglitazone,
metformin, long-acting insulin, and multiple
doses of short-acting insulin, so that potential
Cardiol Ther (2013) 2:1–16 5
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adverse interactions of drugs might be a possible
explanation for the study results [24].
Most importantly, this excessive mortality
was not confirmed in other large scale,
randomized, prospective intervention trials
aiming at lower HbA1c levels done in parallel
to the ACCORD study, such as the Action in
Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled
Evaluation trial (ADVANCE; 11,140 patients
with type 2 diabetes and mean diabetes
duration of 8 years, aiming at a HbA1c level
B6.5% in the intensive arm) [25] and the
Veterans Affairs Diabetes Trial (VADT; 1,791
type 2 diabetic patients with mean diabetes
duration of 11.5 years, aiming at a HbA1c level
B6.0% in the intensive arm) [26]. In fact, several
meta-analyses which included ACCORD,
ADVANCE, VADT, and UKPDS, clearly showed
significant benefits of targeting lower HbA1c
levels for nonfatal myocardial infarction and
total coronary heart disease events [16, 24–28].
On the other hand, hypoglycemia was again a
predictor of CV mortality in these studies,
confirming the findings in the ACCORD study
[24]. Extending the new learnings about
hypoglycemia, it has turned out to be a myth
that higher HbA1c values are protective against
hypoglycemia and the associated CV risks in
insulin treated patients. On the contrary and
counterintuitively, patients on insulin therapy
with higher HbA1c levels may exhibit
hypoglycemia more often than patients on
insulin therapy with close to normal HbA1c
values, as first observed in the UKPDS study
[16]. In addition, when hypoglycemia occurs in
insulinized patients at higher HbA1c levels it
may be more deleterious in terms of CV
fatalities [29].
Target HbA1c levels as near to normal, i.e.,
\7%, yet as safe as possible (so, avoiding
hypoglycemia and weight gain) are the goal
for glycemic control of patients with diabetes.
This requires target ranges of plasma glucose
approximately 90–100 mg/dL (5.0–5.5 mmol/L)
in the fasting and pre-meal state, and\180 mg/
dL (10 mmol/L) postprandially (Fig. 1). Good
glycemic control, however, has to be embedded
into appropriate multifactorial therapy, not
only targeting good glycemic control, but also
control of blood pressure, blood lipids, and
other comorbidities. This approach has been
adopted as the golden treatment paradigm for
patients with type 2 diabetes, based on the
results of the Steno-2 study, which effectively
reduced both microvascular and neuropathic
short-term complications, i.e., within 4 years,
and macrovascular morbidity and longer-term
mortality, i.e., after 8 and 13 years [30].
Last, but not least, it is clear from the
discussion over the appropriate treatment
target that individualization is warranted in
terms of treatment targets and therapy. ‘‘One
size does not fit all’’ and a patient-centred
approach has to consider the patient’s attitude
towards diabetes, biological age, comorbidities,
prior problems with hypoglycemia and weight
gain, short or long duration of diabetes, and
availability of resources. The recent joint
position statement of the American Diabetes
Association (ADA) and the European
Association for the Study of Diabetes (EASD)
has reemphasized this as the core strategy for




Based on the findings of the UKPDS study,
including the ‘‘legacy’’ study [31], metformin is
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the most widely recommended first-line drug
therapy in type 2 diabetes. It should be
emphasized, however, that although the
metformin UKPDS subgroup study looked
encouraging, the results on reducing hard CV
outcomes, including mortality, have never been
confirmed in independent randomized trials,
but only in huge observational data bases [27,
29]. Metformin has a complex mode of action,
largely reducing hepatic glucose output (Fig. 2)
and is especially potent in lowering FPG [32].
Metformin is efficacious, i.e., lowered HbA1c by
1.0–1.5% in randomized controlled trials [33],
causes few hypoglycemic and weight gain
adverse effects, but may cause some
unpleasant gastrointestinal side effects.
Furthermore, the treatment costs are low as
the drug has been available for [50 years and
many generic brands are also on the market.
The most significant limitation is renal
insufficiency (serum creatinine [1.5 mg/dL,
Fig. 1). In addition, it is important for the
cardiologist to withhold the drug 1 day before
angiographic examinations, other imaging
procedures using contrast media, any surgery,
or disease conditions with hypoxemia. With
these contraindications assured, there is
virtually no risk of lactic acidosis as evidenced
in recent Cochrane reviews [34]. Metformin can
also be used safely in patients with
microalbuminurea or heart failure New York
Heart Association (NYHA) classes I and II [35].
Most importantly, metformin remains the
preferred partner in all potential combination
therapies, including with insulin [10]. In light
of this, a wide array of fixed-dose combinations
of metformin with other glucose-lowering drugs
are available on the market, e.g., with
sulfonylureas, pioglitazone, and dipeptidyl
peptidase-4 (DPP-4) inhibitors. A somewhat
unsettled issue is whether metformin therapy
should be implemented together with healthy
life style management as soon as the diagnosis
of diabetes has been made or only after a
Fig. 2 Arguments in favor of early combination therapy. GLP1-Ag glucagon-like peptide-1 agonists
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3-month period of exclusive lifestyle
management, such as in the UKPDS study
[16], which demonstrates the effectiveness of
nonpharmacotherapy to the patient. This may
be, however, an individual decision based on
the condition of the patient and the degree of
baseline metabolic derangement.
Alpha-Glucosidase Inhibitors
An alternate first-line option in some parts of
the world, especially Asian countries, is the class
of alpha-glucosidase inhibitors, e.g., the alpha-
glucosidase inhibitor, acarbose, is the most
widely used oral blood glucose-lowering drug
in China. Alpha-glucosidase inhibitors slow the
digestion of disaccharides and more complex
carbohydrates in the gut, and mainly decrease
postprandial glucose levels [36] (Fig. 2). The
HbA1c-lowering capacity amounts to
approximately 0.8% HbA1c [37]. Problems with
hypoglycemia or weight gain are absent with
the use of these compounds. In fact, weight loss
of approximately 1 kg is usually observed. As
with metformin, some gastrointestinal side
effects may occur, which require a ‘‘start low,
go slow’’ dosage approach, and the costs are
reasonable in view of generic availability. As
with metformin, alpha-glucosidase inhibitors
may be combined with all other treatment
options, including insulin; combination with
insulin seems to be helpful to prevent the
weight gain usually seen with new
implementation of insulin therapy [38]. Based
on post hoc analysis of randomized controlled
trials, alpha-glucosidase inhibitors appear to
have a potential to also reduce CV disease
[39]. Beyond the beneficial effects on
postprandial hyperglycemia and weight, alpha-
glucosidase inhibitors also seem to have a
favorable effect on dyslipidemia, blood
pressure, and the retardation of new
hypertension [39]. This potential to reduce CV
events is currently being further explored in the
randomized controlled Acarbose Cardiovascular
Evaluation trial in China [40].
Combination Therapies
In most patients, combination therapies with
two or three classes of drugs are warranted to
achieve the intended individualized glycemic
control [8, 10, 32] (Fig. 2). The choice of drugs
depends largely on the individual, including
stage and duration of diabetes, problems with
hypoglycemia and weight gain, comorbidities,
fasting hyperglycemia versus postprandial
hyperglycemia, insulin resistance versus
insulin deficiency, and the patient’s preference
are key parameters for the decision (Fig. 3) [10].
Early combination seems to be the golden
strategy as type 2 diabetes is a multi-causal
disease; the various classes of drugs have
distinct and synergistic modes of action, and
the blood glucose-lowering efficacy of these
drugs is more or less fully maintained in
combination. Furthermore, most blood glucose
lowering drugs provide 70–80% of the
maximum effect even at a medium dose, so an
early combination approach is an elegant
strategy to minimize side effects and to
maximize efficacy (Fig. 2).
The recent joint ADA/EASD position
statement [10] mentions five options as step
two of the treatment algorithm for combination
with metformin: sulfonylureas, pioglitazone,
DPP-4 inhibitors, glucagon-like peptide-1
(GLP-1) agonists, and basal insulin (Fig. 3).
Sulfonylureas have been a cornerstone of the
therapy in the UKPDS study and the ADVANCE
trial [16, 25]. They stimulate insulin secretion;
however, their use is burdened by weight gain
and hypoglycemia, and the durability of
efficacy seems to be less sustainable compared
8 Cardiol Ther (2013) 2:1–16
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to metformin or thiazolidindiones (TZD) (A
Diabetes Outcome Progression Trial [ADOPT])
[41]. On the other hand, sulfonylureas are the
most affordable class of blood glucose lowering
drugs, are available worldwide, and generate a
1.00–1.25% effect of lowering HbA1c [42]. As
already mentioned, they have also been used in
the standard care group of the recently
published ORIGIN trial, seemingly with good
long-term success and without major adverse
effects [9]. It is noteworthy, however, that in
large, observational studies the use of
Fig. 3 EASD/ADA position statement 2012: lifestyle plus
initial drug mono and combination therapy. Reproduced
with permission from [10]. ADA American Diabetes
Association, DPP-4 dipeptidyl peptidase-4, EASD Euro-
pean Association for the Study of Diabetes, GI gastroin-
testinal, GLP-1 glucagon-like peptide-1, GLP-1-RA
glucagon-like peptide-1 receptor agonists, HbA1c glycosyl-
ated hemoglobin, SU sulfonylurea, TZD thiazolidinedione.
a Consider beginning at this stage in patients with very high
HbA1c (e.g., C9% [C75 mmol/mol]).
b Consider rapid
acting, nonsulfonylurea secretagogs (meglitinides) in
patients with irregular meal schedules or who develop late
postprandial hypoglycemia on sulfonylureas. c See text box
‘Properties of currently available glucose-lowering agents
that may guide treatment choice in individual patients with
type 2 diabetes mellitus’ [10]. d Usually a basal insulin
(neutral protamine hagedorn, glargine, detemir) in combi-
nation with noninsulin agents. e Certain noninsulin agents
may be continued with insulin
Cardiol Ther (2013) 2:1–16 9
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sulfonylureas is regularly found to be associated
with a poorer CV outcome, including mortality,
in comparison to metformin [43]. In addition,
evidence is emerging that not all sulfonylureas
are alike in this regard; in the nationwide
Danish database, the sulfonylurea, gliclazide,
and the sulfonylurea analog, repaglinide,
outperformed other sulfonylureas and showed
no increased CV morbidity and mortality risk
compared to metformin [43]. The latter drug,
repaglinide, belongs to the class of glinides,
which induce only a short pulse of insulin
secretion (of approximately 1 h), allowing a
more flexible lifestyle omitting or adding
meals, provided the drug is taken immediately
prior to each ingested main meal. Repaglinide is
also interesting in that it is largly eliminated by
the liver, unlike most sulfonylureas, which are
cleared via the kidneys. This allows repaglinide
to be used in cases of some degree of renal
impairment. On the other hand, because of the
liver clearance, repaglinide has the potential to
interfere with other drugs such as gemfibrozil,
clarithromycin, ketoconazol, ciclosporin,
monoamine oxidase (MAO) inhibitors,
angiotensin-converting enzymes (ACE)
inhibitors, salicylates, nonsteroidal anti-
inflammatory drugs (NSAIDs), and other
commonly used drugs, and careful monitoring
of therapy is very important.
TZDs
After the suspension of rosiglitazone due to the
potential negative impact on ischemic heart
disease, pioglitazone has remained the only
TZD widely available. Unlike rosiglitazone,
pioglitazone does not increase LDL cholesterol,
but rather decreases serum triglycerides and
increases high-density lipoprotein (HDL)
cholesterol to some extent, and has shown
encouraging CV outcome results in the
Prospective Pioglitazone Clinical Trial in
Macrovascular Events (PROACTIVE; 5,238 high
CV risk, type 2 diabetic patients with
preexisting CV events). As peroxisome
proliferator-activated receptor (PPAR)-gamma
agonists, each TZD exhibits a unique pattern
of gene activation. Pioglitazone regulates fatty
acid storage; adipocyte differentiation and, via
insulin sensitization, glucose metabolism
(Fig. 2). In addition, pioglitazone shows
numerous anti-inflammatory effects, raises
adiponectin, and impacts favorably on
endothelial cells. Clinically, pioglitazone
predominantly reduces fasting hyperglycemia
by its inhibitory effect on hepatic glucose
output and also reduces hepatic triglyceride
content. The HbA1c-lowering effect ranges from
1.00 to 1.25% [42]. Adverse effects include
weight gain (especially of the subcutaneous
compartment) of some 2–3 kg on average,
potentially due to fluid retention, and an
elevated risk of peripheral bone fractures in
women. Pioglitazone is contraindicated in heart
failure patients with NYHA classes II–IV.
Likewise, it should not be used in patients
with a history of bladder cancer, as there seems
to be a slight, but significant, increased relative
risk of bladder tumors of 10–20% associated
with the use of pioglitazone. Pioglitazone has
been prospectively evaluated in patients with
type 2 diabetes in the PROACTIVE trial [44]. The
majority of experts feel that this double-blind,
controlled trial with a 3-year follow-up was a
positive trial showing a reduction of CV events
of some 15%, although the primary composite
outcome parameter, which included also lower
limb revascularizations, demonstrated a
nonsignificant advantageous trend associated
with pioglitazone treatment. Patients with
preexisting myocardial infarction or stroke
clearly benefited from this therapy in the
PROACTIVE trial. Recently, presentations at
10 Cardiol Ther (2013) 2:1–16
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the EASD Annual Meeting in September 2012
underlined that during an observational follow-
up of 6 years after the end of the PROACTIVE
trial, there was neither an excessive rate of
bladder malignancies in patients on prior
pioglitazone therapy, nor did the favorable CV
outcomes persist during the observational
follow-up in the absence of continued
pioglitazone treatment [45, 46]. Furthermore, a
meta-analysis of all available randomized trials
comparing pioglitazone use with placebo or an
active comparator in 22,718 patients with type
2 diabetes confirmed an 18% reduction of major
adverse CV events (MACE) in patients on
pioglitazone treatment [47].
In aggregate, the use of pioglitazone needs
experienced differentiation at the level of the
individual patient. On the other hand, it
provides a powerful, sustainable therapy, best
used in combination with metformin, alpha-
glucosidase inhibitors, or incretin based
therapies, as these combinations minimize any
problems with weight gain and maximize blood
glucose-lowering capacity without the risk of
hypoglycemia.
DPP-4 Inhibitors
DPP-4 inhibitors are a class of drugs whose use is
on the rise [10, 23]. They seem to be very well
tolerated, yet their efficacy (0.7–1.0% HbA1c-
lowering capacity) appears to be somewhat less
than that of metformin, pioglitazone, or
sulfonylureas [48]. They increase insulin
secretion (Fig. 2) and reduce inadequately high
glucagon levels after a meal by their inhibitory
effect on the degradation of the physiologically
released incretine hormone, GLP-1, from L-cells
in the small intestines. DPP-4 inhibitors are
seen as weight neutral and have very little risk
of hypoglycemia, in contrast to sulfonylureas.
They mainly reduce postprandial
hyperglycemia and are ideal partners for
combination therapies, particularly with
metformin (where there seems to be
synergistic effects on GLP-1 levels), alpha-
glucosidase inhibitors, or pioglitazone.
Sitagliptin is the most widely used compound
of this class; its labeling also allows
monotherapy and combination with insulin.
All DPP-4 inhibitors (with the exception of
vildagliptin) are currently evaluated in
prospective, randomized, controlled trials for
vascular and other outcomes, the results of
which will be available from 2015/16 onwards.
GLP-1 Agonists
GLP-1 agonists are another option of incretin-
based therapies [10, 23, 32]. They are a group of
injectable compounds used in pharmacological
doses. The molecules are derivatives of the
natural incretine hormone, GLP-1, and are
resistant to the physiological degradation
process by the DPP-4 enzyme. They bind to
the GLP-1 receptors and induce GLP-1
signaling. Beyond the already mentioned
effects of stimulating insulin secretion and
inhibiting glucagon release, GLP-1 agonists
also inhibit appetite via complex mechanisms
on the brain, and delay gastric emptying. The
latter effect may generate gastrointestinal side
effects, including nausea, vomiting, and, in
some cases, diarrhoea. This potential warrants
a ‘‘start low, go slow’’ therapy approach. The
HbA1c-lowering capacity is superior to DPP-4
inhibitors (1.0–1.5% HbA1c) and therapy is
usually associated with a significant weight
loss of 3–5 kg on average [49]. Dosing and
effect on the blood glucose pattern depend on
the formulation. Short-acting exenatide mainly
reduces postprandial hyperglycemia and
requires twice-daily dosing. Longer-acting
liraglutide decreases both fasting and
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postprandial hyperglycemia and is dosed once
daily, whereas very long-acting exenatide is
injected once a week and lowers the whole
24-h blood glucose profile. Like DPP-4
inhibitors, both available GLP-1 agonists are
currently being studied in long-term
randomized controlled trials looking at CV
outcomes, addressing both the exclusion of
potential CV harm and clear CV benefits.
These studies are also expected to clarify the
ongoing debate of whether incretin-based
therapies might be associated with an
increased risk of pancreatitis and even
pancreatic carcinoma. Liraglutide has also
raised concerns over a somewhat increased risk
of medullary thyroid cancer, as seen in two
animal species [50]. GLP-1 agonists can be
combined with metformin or other
noninsulinotropic blood glucose-lowering
drugs with little risk of hypoglycemia.
Combinations with DPP-4 inhibitors are not
recommended, and combinations with
sulfonylureas or insulin need to be monitored
for the risk of hypoglycemia. GLP-1 agonists are
also useful in triple combination therapies and
seem to be effective to postpone the need for
complex insulin therapy in type 2 diabetes long
term.
Long-Acting Insulin
Long-acting insulin, typically as a long-acting
insulin analog, in combination with metformin
is seen as one of five options of the second step
combinations in the recent joint ADA/EASD
treatment algorithm for type 2 diabetes (Fig. 3)
[10]. Other guidelines delay the use of insulin in
general until the third step in the treatment
algorithm [12]. In theory, and depending upon
the insulin dose used, insulin therapy should
yield nearly unlimited efficacy, were it not for
the risk of hypoglycemia and weight gain. In
most studies, an HbA1c-lowering capacity of
1.0–2.0% is attained. Long-acting insulin
targeting fasting blood glucose was one of the
key therapeutic components used in the UKPDS
study and was found to be associated with
significant outcome benefits, including the
‘‘legacy’’ effect on overall mortality and
myocardial infarction [16, 31]. The term
‘‘legacy’’ effect refers to the fact that a
significant benefit emerged for mortality and
myocardial infarction, which had not be seen in
this clarity earlier, 10 years after the end of the
randomized controlled trial phase of UKPDS
and despite no further significant difference of
HbA1c values, compared to the less intensive
treatment group [31]. Long-acting insulin was
also used in the recently published ORIGIN trial
[9]. Lessons from this and other trials seem to
indicate very little risk of weight gain and
hypoglycemia if long-acting insulin is used in
the early stages of type 2 diabetes. Also, neither
the debated cancer issue nor assumed increased
risk of CV complications seems to be
substantiated in association with the early use
of insulin, even in patients with preexisting CV
disease. On the other hand, and
notwithstanding the potential of another
‘‘legacy’’ effect in the future, in view of the
absence of a specific beneficial effect in the
ORIGIN trial as compared to more conventional
therapies with metformin and sulfonylureas,
long-acting insulin seems to be only one option
among others for second step therapy.
Triple Combination Therapies
The recent joint ADA/EASD position statement
officially recognizes triple combination
therapies as a useful third step in the
treatment algorithm of type 2 diabetes (Fig. 3)
[10]. Triple combinations are composed of the
classes of drugs already discussed so far, and are
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tailored to the needs of the individual patient.
They may consider the individual metabolic
phenotype, avoiding hypoglycemia, weight
gain, coexisting nonalcoholic fatty liver
disease, and other comorbidities, as well as the
patient’s preferences and availabilities of
resources.
In case individual treatment options are still
not met despite triple combination therapies,
alternate triple combinations may be tried
under inclusion of injectables (GLP-1 agonists,
if warranted, or long-acting insulin). In patients
with a longer duration of the disease, often
more complex insulin strategies may be needed
as a fourth treatment step (Fig. 3). Depending
on the daily blood glucose (and lifestyle)
pattern, intensification of insulin therapy can
be achieved by adding one or two pre-meal
injections of short-acting insulin (analogs) to
long-acting insulin at bedtime or before supper,
by switching to twice-daily premixed insulin
injections of short- and long-acting insulin
before breakfast and supper, or by going to
full-scale intensified insulin therapy with
sufficient coverage of the 24-h basal insulin
demand and short-acting insulin (analogs)
before each main meal. Continuation of
metformin therapy is widely recommended
along with more complex insulin strategies to
preserve the specific benefits of this therapy and
reduce the daily insulin dose. Similarly, alpha-
glucosidase inhibitors have been used to
minimize the weight gain issue with stepping
up insulin therapy in some parts of the world. A
new emerging strategy, depending on
availability, seems to be the combination of
long-acting insulins for coverage of the basal
24-h insulin demand and GLP-1 agonists to
control the postprandial rise of blood glucose,
again in conjunction with metformin.
In aggregate, a patient-centred approach is
crucial for successful glycemic control. The
availability of a continuously growing and
enormously wide spectrum of treatment
options and rather complex differentiations
may look overwhelming at times. More
complex therapies might warrant the
cooperation with a diabetologist/
endocrinologist, and the need for education
and training on the side of the patients, which
usually requires a specialized centre, is required.
CONCLUSION
New classes of blood glucose-lowering drugs
will shortly hit the market and increase the
complexity further. A ‘‘magic bullet,’’ however,
that does it all in one is not on the horizon, and
the complexity of therapy will certainly remain
with us for the next decade. In view of the
millions of people worldwide with undiagnosed
or, if diagnosed, poorly controlled diabetes, the
biggest contemporary challenge is inertia to
diagnose and treat diabetes properly. The
intricate, yet intense, interaction between
diabetes mellitus and CV complications gives
the cardiologist a unique opportunity to set the
scene for appropriate diagnostic and
therapeutic movements at the crossroads of
metabolic and vascular diseases.
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